tiprankstipranks
Trending News
More News >
Viridian Therapeutics (VRDN)
NASDAQ:VRDN

Viridian Therapeutics (VRDN) AI Stock Analysis

Compare
1,373 Followers

Top Page

VR

Viridian Therapeutics

(NASDAQ:VRDN)

41Neutral
Viridian Therapeutics is currently facing significant hurdles due to its financial struggles, particularly the absence of revenue and ongoing losses. The challenging technical indicators further weigh on the stock's outlook. However, the recent addition of a seasoned executive to the board and a strong cash position offer some potential for improvement if strategic initiatives are effectively implemented.
Positive Factors
Financial Performance
The target price for VRDN has increased to $48, reflecting positive developments and future potential.
Market Potential
Management is confident that veligrotug will capture a significant market share upon launch.
Product Development
The company reported top-line data for the second Phase 3 veligrotug (VRDN-001) study, meeting all key primary and secondary efficacy endpoints.
Negative Factors
Development Stage
There is little value ascribed to the FcRn inhibitor franchise at present given the development stage of the programs.
Investment Risk
There is little downside risk associated with the VRDN-008 readout given its development stage, while positive data will help draw greater investor attention towards the FcRn.
Market Competition
Chronic TED does not appear on Tepezza's label, which gives the company greater freedom to promote veligrotug's data.

Viridian Therapeutics (VRDN) vs. S&P 500 (SPY)

Viridian Therapeutics Business Overview & Revenue Model

Company DescriptionViridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
How the Company Makes MoneyViridian Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model typically involves the sale of pharmaceutical products upon receiving regulatory approval and successfully launching them to the market. Additionally, Viridian may engage in strategic collaborations and partnerships with other pharmaceutical companies to co-develop therapies, which can provide milestone payments, royalties, and licensing fees as additional revenue streams. These partnerships can also enhance the company's research and development capabilities while expanding its market reach for the commercialized therapies.

Viridian Therapeutics Financial Statement Overview

Summary
Viridian Therapeutics faces significant financial challenges with no revenue generation in 2024, consistent operational inefficiencies, and negative free cash flow. Despite a strong cash position and low leverage, the sustainability risks due to ongoing losses and cash burn rate are concerning.
Income Statement
30
Negative
Viridian Therapeutics has struggled with revenue generation, evident from the decrease in total revenue from $4.46M in 2019 to zero in 2024, indicating significant challenges in market traction or product development. Consistently negative net income and EBIT highlight ongoing operational inefficiencies. The company also experienced declining gross and net profit margins over the years, reflecting persistent unprofitability.
Balance Sheet
40
Negative
The balance sheet reveals a strong cash position with cash and cash equivalents growing to $717.6M by 2024, but the absence of revenue poses a risk to long-term sustainability. The company's debt-to-equity ratio is favorable due to minimal debt, suggesting low leverage. However, a consistent decline in equity ratio from 52% in 2019 to 90% in 2024 reflects potential over-reliance on equity financing.
Cash Flow
45
Neutral
Operating cash flow has been consistently negative, indicating that the company is not generating sufficient cash from its core operations. While there is a notable increase in financing cash flow, reflecting successful fundraising efforts, free cash flow remains negative, pointing to potential cash burn issues. The absence of revenue growth and high cash burn rate are concerning for future liquidity.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
302.00K314.00K1.77M2.96M1.05M
Gross Profit
302.00K-1.01M1.02M2.34M-27.25M
EBIT
-299.04M-254.45M-134.30M-79.73M-110.38M
EBITDA
-266.36M-234.56M-128.63M-78.79M-109.67M
Net Income Common Stockholders
-269.95M-237.73M-125.44M-79.42M-110.98M
Balance SheetCash, Cash Equivalents and Short-Term Investments
717.58M477.37M424.55M196.97M127.64M
Total Assets
742.40M490.42M435.09M203.71M131.25M
Total Debt
21.09M21.05M5.26M520.00K455.00K
Net Debt
-78.50M-81.78M-150.32M-41.78M-45.44M
Total Liabilities
70.76M48.40M40.03M15.99M11.22M
Stockholders Equity
671.64M442.02M395.06M187.72M120.04M
Cash FlowFree Cash Flow
-232.83M-185.07M-94.64M-54.92M-29.82M
Operating Cash Flow
-232.32M-184.17M-93.84M-54.58M-29.78M
Investing Cash Flow
-228.65M-94.25M-115.13M-74.29M-50.48M
Financing Cash Flow
457.74M225.67M322.24M125.28M101.31M

Viridian Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price13.74
Price Trends
50DMA
14.27
Negative
100DMA
16.53
Negative
200DMA
18.07
Negative
Market Momentum
MACD
-0.17
Negative
RSI
52.03
Neutral
STOCH
47.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Neutral. The current price of 13.74 is above the 20-day moving average (MA) of 12.80, below the 50-day MA of 14.27, and below the 200-day MA of 18.07, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 52.03 is Neutral, neither overbought nor oversold. The STOCH value of 47.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VRDN.

Viridian Therapeutics Risk Analysis

Viridian Therapeutics disclosed 67 risk factors in its most recent earnings report. Viridian Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Viridian Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
$1.13B213.471.52%33.97%
52
Neutral
$5.28B3.75-42.72%2.86%17.70%2.03%
WVWVE
51
Neutral
$1.19B-73.24%-4.42%-42.17%
48
Neutral
$1.11B-57.48%13698.99%31.46%
48
Neutral
$1.19B-75.69%-25.83%
43
Neutral
$910.79M-66.09%32387.34%15.93%
41
Neutral
$1.11B-45.77%-3.82%29.10%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VRDN
Viridian Therapeutics
13.74
-1.66
-10.78%
GERN
Geron
1.43
-2.50
-63.61%
IOVA
Iovance Biotherapeutics
3.33
-10.30
-75.57%
AUPH
Aurinia Pharmaceuticals
8.20
3.10
60.78%
WVE
Wave Life Sciences
7.94
1.80
29.32%
SNDX
Syndax Pharmaceuticals
13.82
-8.23
-37.32%

Viridian Therapeutics Earnings Call Summary

Earnings Call Date:Feb 27, 2025
(Q1-2024)
|
% Change Since: -11.53%|
Next Earnings Date:May 07, 2025
Earnings Call Sentiment Positive
The earnings call reflects significant progress and positive developments in the company's pipeline, particularly with the completion of enrollment in the THRIVE trial, a strong financial position, and positive regulatory interactions. However, there are challenges, such as the extended timeline for BLA submission and concerns about hearing impairment assessments in clinical trials.
Q1-2024 Updates
Positive Updates
Completion of THRIVE Phase III Enrollment
The THRIVE Phase III trial evaluating 001 in patients with active TED completed enrollment ahead of schedule with 113 patients, exceeding the target of 90 due to strong patient demand.
Strong Financial Position
Viridian ended the quarter with $613 million in cash, cash equivalents, and short-term investments, maintaining a cash runway into the second half of 2026.
Positive FDA Meeting for Subcutaneous 003 Program
The company completed a positive Type C meeting with the FDA for the subcutaneous 003 program and is on track to initiate pivotal clinical trials midyear.
Progress in FcRn Portfolio
Viridian is making progress with its FcRn portfolio, aiming to file an IND for 006 by the end of the year, and plans to share 008 nonhuman primate data in the second half of 2024.
Negative Updates
Extended Timeline for BLA Submission
The BLA submission for the 001 program is anticipated in the second half of 2025, driven primarily by the extended follow-up period in the THRIVE 2 trial.
Challenges in Hearing Impairment Assessment
There are concerns about controlling for hearing impairment events in the THRIVE study due to factors already present in TED patients.
Company Guidance
During Viridian Therapeutics' Q1 2024 earnings call, the company provided several updates on their pipeline and financial outlook. Viridian announced the completion of enrollment for their THRIVE Phase III trial for the 001 IV program, surpassing the target with 113 patients. They anticipate top-line results in September 2024 and plan a BLA submission for the 001 program in the second half of 2025. The company also highlighted progress in their FcRn portfolio, with an IND for 006 expected by the end of 2024 and 008 nonhuman primate data anticipated in the second half of 2024. Viridian ended the quarter with $613 million in cash, cash equivalents, and short-term investments, maintaining a cash runway into the second half of 2026.

Viridian Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Viridian Therapeutics Appoints Jeff Ajer to Board
Positive
Apr 7, 2025

On April 7, 2025, Viridian Therapeutics announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer brings over 25 years of experience in commercialization for rare diseases, having previously served as Chief Commercial Officer at BioMarin Pharmaceutical. His expertise is expected to bolster Viridian’s commercial strategy as the company advances its pipeline, including veligrotug for thyroid eye disease. Additionally, Viridian announced inducement grants of stock options to new employees, aligning with its growth and recruitment strategies.

Spark’s Take on VRDN Stock

According to Spark, TipRanks’ AI Analyst, (VRDN) is a Neutral.

Viridian Therapeutics’ stock score reflects significant financial challenges and poor technical indicators, offset by positive corporate developments. The absence of revenue and negative cash flows highlight major risks, while the promising clinical trial results offer potential upside. Overall, the stock faces substantial hurdles but has opportunities if it can capitalize on its recent clinical success.

To see Spark’s full report on (VRDN) stock, click here.

Private Placements and Financing
Viridian Therapeutics Enters New $300M Sale Agreement
Neutral
Mar 4, 2025

On March 3, 2025, Viridian Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $300 million in common stock to support clinical development and commercialization efforts. This new agreement replaces a prior sale agreement from September 2022, which was terminated after selling $115.2 million in stock, with no costs associated with its early termination.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.